股本结构
单位：万股
| 公告日期 | 2026-08-14 | 2026-07-23 | 2026-08-14 | 2026-06-12 | 2026-04-30 | 2026-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 651.15 | 641.65 | 425.51 | 421.93 | 418.75 | 416.87 |
| 普通股本 | 651.15 | 641.65 | 425.51 | 421.93 | 418.75 | 416.87 |
| 优先股 | 未披露 | 未披露 | 0.11 | 未披露 | 未披露 | 0.11 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-10 | 2026-07-22 | 2026-06-30 | 2026-06-11 | 2026-04-28 | 2026-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-14 | 651.15 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-07-23 | 641.65 | 未披露 | 定期报告 | 2026-07-22 |
| 2026-08-14 | 425.51 | 0.11 |
更多>>
From March 31, 2026 to June 30, 2026
Issuance of common stock in settlement of vested restricted stock units
Loan agreement interest settled in stock
Issuance of shares under the sales agreement, net of issuance costs
|
2026-06-30 |
| 2026-06-12 | 421.93 | 未披露 | 定期报告 | 2026-06-11 |
| 2026-04-30 | 418.75 | 未披露 | 定期报告 | 2026-04-28 |
| 2026-05-15 | 416.87 | 0.11 |
更多>>
From January 1,2026 to March 31,2026
Issuance of common stock in settlement of vested restricted stock units
Issuance of shares under the sales agreement, net of issuance costs
|
2026-03-31 |
| 2026-03-31 | 416.42 | 未披露 | 定期报告 | 2026-03-27 |
| 2026-03-04 | 404.83 | 未披露 |
更多>>
a reverse stock split of its common stock at a ratio of 50 for 1
|
2026-03-06 |
| 2026-03-04 | 20241.66 | 未披露 | 定期报告 | 2026-03-03 |
| 2026-01-26 | 20152.23 | 未披露 | 定期报告 | 2026-01-21 |
| 2026-01-26 | 20141.73 | 未披露 | 定期报告 | 2026-01-14 |
| 2025-11-14 | 19868.99 | 未披露 | 定期报告 | 2025-11-12 |
| 2025-11-14 | 19739.14 | 0.11 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in settlement of vested restricted stock units
Issuance of shares under the sales agreement, net of issuance costs
|
2025-09-30 |
| 2025-08-14 | 19670.51 | 未披露 | 定期报告 | 2025-08-13 |
| 2025-08-14 | 19369.34 | 0.11 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock in settlement of vested restricted stock units
|
2025-06-30 |
| 2025-07-10 | 19369.34 | 未披露 | 定期报告 | 2025-06-27 |
| 2025-06-20 | 18444.34 | 未披露 | 定期报告 | 2025-06-16 |
| 2025-05-14 | 18389.34 | 0.11 |
更多>>
From January 1, 2025 to March 31, 2025
Issuance of common stock in settlement of vested restricted stock units
|
2025-03-31 |
| 2025-04-02 | 18389.34 | 未披露 | 定期报告 | 2025-03-21 |
| 2025-04-02 | 17799.14 | 0.11 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of Series A preferred stock
Issuance of Series C preferred stock
Issuance of Series B preferred stock
Merger, net of redemptions and transaction costs
Issuance of restricted common stock
Issuance of common stock for Sponsor advisory service fee
Issuance of commitment shares in connection with the loan agreement
Issuance of common stock in connection with Polar note
Contribution from related party
Issuance of common stock in settlement of vested restricted stock units
|
2024-12-31 |
| 2024-11-19 | 17505.12 | 未披露 | 定期报告 | 2024-11-15 |
| 2024-11-19 | 17077.39 | 0.09 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of Series C preferred stock
Issuance of preferred stock
Issuance of common stock in settlement of vested restricted stock units
|
2024-09-30 |
| 2024-08-14 | 17064.69 | 未披露 | 定期报告 | 2024-08-12 |
| 2024-08-01 | 17000.05 | 未披露 | 定期报告 | 2024-07-30 |
| 2024-08-14 | 16882.64 | 0.05 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with Polar note payable
Issuance of commitment shares in connection with the Loan Agreement
Issuance of common stock in settlement of vested restricted stock units
|
2024-06-30 |
| 2024-06-21 | 16711.44 | 未披露 | 定期报告 | 2024-06-20 |
| 2024-05-28 | 16611.44 | 未披露 | 定期报告 | 2024-05-24 |
| 2024-05-28 | 16461.44 | 0.41 |
更多>>
From January 1, 2024 to March 31, 2024
Conversion of convertible promissory notes into common stock in connection with merger
Issuance of common stock for Sponsor advisory service fee
Issuance of restricted common stock
Merger, net of redemptions and transaction costs
|
2024-03-31 |
| 2024-02-14 | 16542.11 | 未披露 |
更多>>
On February 14, 2024 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of Semper Paratus (the “Merger,” and together with the other transactions contemplated by the Merger Agreement, the “Business Combination”).
|
2024-02-15 |
| 2024-04-29 | 1493.55 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Conversion of Class B shares
|
2023-12-31 |
| 2023-12-22 | 1493.55 | 未披露 | 定期报告 | 2023-12-18 |
| 2023-08-21 | 1581.64 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-05-22 | 1581.64 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Conversion of Class B shares
|
2023-03-31 |
| 2022-05-17 | 4793.33 | 未披露 | 定期报告 | 2022-03-31 |
| 2021-12-17 | 4648.33 | 未披露 | 定期报告 | 2022-01-04 |
From March 31, 2026 to June 30, 2026
Issuance of common stock in settlement of vested restricted stock units
Loan agreement interest settled in stock
Issuance of shares under the sales agreement, net of issuance costs
From January 1,2026 to March 31,2026
Issuance of common stock in settlement of vested restricted stock units
Issuance of shares under the sales agreement, net of issuance costs
a reverse stock split of its common stock at a ratio of 50 for 1
From June 30, 2025 to September 30, 2025
Issuance of common stock in settlement of vested restricted stock units
Issuance of shares under the sales agreement, net of issuance costs
From March 31, 2025 to June 30, 2025
Issuance of common stock in settlement of vested restricted stock units
From January 1, 2025 to March 31, 2025
Issuance of common stock in settlement of vested restricted stock units
From December 31, 2023 to December 31, 2024
Issuance of Series A preferred stock
Issuance of Series C preferred stock
Issuance of Series B preferred stock
Merger, net of redemptions and transaction costs
Issuance of restricted common stock
Issuance of common stock for Sponsor advisory service fee
Issuance of commitment shares in connection with the loan agreement
Issuance of common stock in connection with Polar note
Contribution from related party
Issuance of common stock in settlement of vested restricted stock units
From June 30, 2024 to September 30, 2024
Issuance of Series C preferred stock
Issuance of preferred stock
Issuance of common stock in settlement of vested restricted stock units
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with Polar note payable
Issuance of commitment shares in connection with the Loan Agreement
Issuance of common stock in settlement of vested restricted stock units
From January 1, 2024 to March 31, 2024
Conversion of convertible promissory notes into common stock in connection with merger
Issuance of common stock for Sponsor advisory service fee
Issuance of restricted common stock
Merger, net of redemptions and transaction costs
On February 14, 2024 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub merged with and into Tevogen Bio, with Tevogen Bio being the surviving company and a wholly owned subsidiary of Semper Paratus (the “Merger,” and together with the other transactions contemplated by the Merger Agreement, the “Business Combination”).
From December 31, 2022 to December 31, 2023
Conversion of Class B shares
From January 1, 2023 to March 31, 2023
Conversion of Class B shares